Drug Profile
Peptide YY3-36 - Gila Therapeutics
Alternative Names: GT 001 - Gila Therapeutics; GT 002 - Gila Therapeutics; GT 003 - Gila Therapeutics; GT-001; GT-002; GT-003; Peptide YY (3-36); Peptide YY3-36; PYY(3-36); PYY3-36Latest Information Update: 31 Jan 2023
Price :
$50
*
At a glance
- Originator Gila Therapeutics
- Class Antihyperglycaemics; Hormones; Obesity therapies; Peptides
- Mechanism of Action Peptide YY (3-36) replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Obesity
- No development reported Diabetes mellitus
Most Recent Events
- 31 Jan 2023 GT 001 is still in phase I trials for Obesity in USA (Gila Therapeutics pipeline, January 2023)
- 31 Jan 2023 Gila Therapeutics plans to initiate second clinical study in Obesity (Gila Therapeutics pipeline, January 2023)
- 28 Jul 2022 No recent reports of development identified for research development in Diabetes-mellitus in USA (PO)